Not so pseudo anymore: Pseudogenes as therapeutic targets

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 2023-2034

  Roberts, Thomas C ^a,b   Morris, Kevin V ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

epigenetics; lncRNAs; long noncoding RNAs; microRNA; miRNA; pseudogenes; therapeutics

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; LONG UNTRANSLATED RNA; MESSENGER RNA; SMALL INTERFERING RNA;

BIOGENESIS; DNA TRANSPOSITION; EPIGENETICS; GENE CLUSTER; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC CODE; GENETIC VARIABILITY; HDAC1 GENE; HMGA1 GENE; HUMAN; NONHUMAN; PSEUDOGENE; PTENP1 GENE; REVIEW; RNA INTERFERENCE; RNA STABILITY; RNA TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION; GENOME, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; PSEUDOGENES; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; TRANSCRIPTION, GENETIC;

EID: 84888992963     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.172     Document Type: Review

References (95)

1. Vanin EF. Processed pseudogenes: characteristics and evolution. Annu. Rev. Genet. 19, 253-272 (1985).
2. Mighell AJ, Smith NR, Robinson PA, Markham AF. Vertebrate pseudogenes. FEBS Lett. 468(2-3), 109-114 (2000).
3. Jacq C, Miller JR, Brownlee GG. A pseudogene structure in 5S DNA of Xenopus laevis. Cell 12(1), 109-120 (1977).
4. Ohshima K, Hattori M, Yada T, Gojobori T, Sakaki Y, Okada N. Whole-genome screening indicates a possible burst of formation of processed pseudogenes and Alu repeats by particular L1 subfamilies in ancestral primates. Genome Biol. 4(11), R74 (2003).
5. Harrison PM, Hegyi H, Balasubramanian S et al. Molecular fossils in the human genome: identification and analysis of the pseudogenes in chromosomes 21 and 22. Genome Res. 12(2), 272-280 (2002).
6. Gonçalves I, Duret L, Mouchiroud D. Nature and structure of human genes that generate retropseudogenes. Genome Res. 10(5), 672-678 (2000).
7. Ohno S. So much 'junk' DNA in our genome. Brookhaven Symp. Biol. 23, 366-370 (1972).
8. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
9. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
10. Britten RJ, Davidson EH. Gene regulation for higher cells: a theory. Science 165(3891), 349-357 (1969).
11. Britten RJ, Davidson EH. Repetitive and non-repetitive DNA sequences and a speculation on the origins of evolutionary novelty. Q. Rev. Biol. 46(2), 111-138 (1971).
12. Niimura Y, Nei M. Extensive gains and losses of olfactory receptor genes in mammalian evolution. PLoS ONE 2(8), e708 (2007).
13. Freitag J, Ludwig G, Andreini I, Rössler P, Breer H. Olfactory receptors in aquatic and terrestrial vertebrates. J. Comp. Physiol. A 183(5), 635-650 (1998).
14. Zhu J, Sanborn JZ, Diekhans M, Lowe CB, Pringle TH, Haussler D. Comparative genomics search for losses of long-established genes on the human lineage. PLoS Comput. Biol. 3(12), e247 (2007).
15. Duret L, Chureau C, Samain S, Weissenbach J, Avner P. The Xist RNA gene evolved in eutherians by pseudogenization of a protein-coding gene. Science 312(5780), 1653-1655 (2006).
16. Zhang ZD, Frankish A, Hunt T, Harrow J, Gerstein M. Identification and analysis of unitary pseudogenes: historic and contemporary gene losses in humans and other primates. Genome Biol. 11(3), R26 (2010).
17. Nishikimi M, Yagi K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am. J. Clin. Nutr. 54(6 Suppl.), 1203S-1208S (1991).
18. Soskine M, Tawfik DS. Mutational effects and the evolution of new protein functions. Nat. Rev. Genet. 11(8), 572-582 (2010).
19. Hill AV, Nicholls RD, Thein SL, Higgs DR. Recombination within the human embryonic xi-globin locus: a common xi-xi chromosome produced by gene conversion of the psi xi gene. Cell 42(3), 809-819 (1985).
20. Esnault C, Maestre J, Heidmann T. Human LINE retrotransposons generate processed pseudogenes. Nat. Genet. 24(4), 363-367 (2000).
21. Vinckenbosch N, Dupanloup I, Kaessmann H. Evolutionary fate of retroposed gene copies in the human genome. Proc. Natl Acad. Sci. USA 103(9), 3220-3225 (2006).
22. Jurka J. Sequence patterns indicate an enzymatic involvement in integration of mammalian retroposons. Proc. Natl Acad. Sci. USA 94(5), 1872-1877 (1997).
23. Zheng D, Frankish A, Baertsch R et al. Pseudogenes in the ENCODE regions: consensus annotation, analysis of transcription, and evolution. Genome Res. 17(6), 839-851 (2007).
24. Zhang Z, Harrison P, Gerstein M. Identification and analysis of over 2000 ribosomal protein pseudogenes in the human genome. Genome Res. 12(10), 1466-1482 (2002).
25. McDonell L, Drouin G. The abundance of processed pseudogenes derived from glycolytic genes is correlated with their expression level. Genome 55(2), 147-151 (2012).
26. Frith MC, Wilming LG, Forrest A et al. Pseudo-messenger RNA: phantoms of the transcriptome. PLoS Genet. 2(4), e23 (2006).
27. Harrison PM, Zheng D, Zhang Z, Carriero N, Gerstein M. Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability. Nucleic Acids Res. 33(8), 2374-2383 (2005).
28. Hawkins PG, Morris KV. Transcriptional regulation of Oct4 by a long non-coding RNA antisense to Oct4-pseudogene 5. Transcription 1(3), 165-175 (2010).
29. Korneev SA, Park JH, O'Shea M. Neuronal expression of neural nitric oxide synthase (nNOS) protein is suppressed by an antisense RNA transcribed from an NOS pseudogene. J. Neurosci. 19(18), 7711-7720 (1999).
30. Johnsson P, Ackley A, Vidarsdottir L et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat. Struct. Mol. Biol. 20(4), 440-446 (2013).
31. Clark MB, Amaral PP, Schlesinger FJ et al. The reality of pervasive transcription. PLoS Biol. 9(7), e1000625; discussion e1001102 (2011).
32. Gerstein MB, Bruce C, Rozowsky JS et al. What is a gene, post-ENCODE? history and updated definition. Genome Res. 17(6), 669-681 (2007).
33. Djebali S, Davis CA, Merkel A et al. Landscape of transcription in human cells. Nature 489(7414), 101-108 (2012).
34. Graur D, Zheng Y, Price N, Azevedo RBR, Zufall RA, Elhaik E. On the immortality of television sets: 'function' in the human genome according to the evolution-free gospel of ENCODE. Genome Biol. Evol. 5(3), 578-590 (2013).
35. Khachane AN, Harrison PM. Assessing the genomic evidence for conserved transcribed pseudogenes under selection. BMC Genomics 10, 435 (2009).
36. Podlaha O, Zhang J. Nonneutral evolution of the transcribed pseudogene Makorin1-p1 in mice. Mol. Biol. Evol. 21(12), 2202-2209 (2004).
37. Svensson O, Arvestad L, Lagergren J. Genome-wide survey for biologically functional pseudogenes. PLoS Comput. Biol. 2(5), e46 (2006).
38. Pei B, Sisu C, Frankish A et al. The GENCODE pseudogene resource. Genome Biol. 13(9), R51 (2012).
39. Taft RJ, Mattick JS. Increasing biological complexity is positively correlated with the relative genome-wide expansion of non-protein-coding DNA sequences. Genome Biol. 5(1), P1 (2003).
40. Baltimore D. Our genome unveiled. Nature 409(6822), 814-816 (2001).
41. Novikova IV, Hennelly SP, Sanbonmatsu KY. Structural architecture of the human long non-coding RNA, steroid receptor RNA activator. Nucleic Acids Res. 40(11), 5034-5051 (2012).
42. Kleene KC, Mulligan E, Steiger D, Donohue K, Mastrangelo MA. The mouse gene encoding the testis-specific isoform of poly(A) binding protein (Pabp2) is an expressed retroposon: intimations that gene expression in spermatogenic cells facilitates the creation of new genes. J. Mol. Evol. 47(3), 275-281 (1998).
43. Kalyana-Sundaram S, Kumar-Sinha C, Shankar S et al. Expressed pseudogenes in the transcriptional landscape of human cancers. Cell 149(7), 1622-1634 (2012).
44. Olsen MA, Schechter LE. Cloning, mRNA localization and evolutionary conservation of a human 5-HT7 receptor pseudogene. Gene 227(1), 63-69 (1999).
45. Elliman SJ, Wu I, Kemp DM. Adult tissue-specific expression of a Dppa3-derived retrogene represents a postnatal transcript of pluripotent cell origin. J. Biol. Chem. 281(1), 16-19 (2006).
46. Lin M, Pedrosa E, Shah A et al. RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS ONE 6(9), e23356 (2011).
47. Han YJ, Ma SF, Yourek G, Park YD, Garcia JGN. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J. 25(7), 2305-2312 (2011).
48. Suo G, Han J, Wang X et al. Oct4 pseudogenes are transcribed in cancers. Biochem. Biophys. Res. Commun. 337(4), 1047-1051 (2005).
49. Bier A, Oviedo-Landaverde I, Zhao J, Mamane Y, Kandouz M, Batist G. Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target. Mol. Cancer Ther. 8(4), 786-793 (2009).
50. Zou M, Baitei EY, Alzahrani AS et al. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors. Neoplasia 11(1), 57-65 (2009).
51. Feenstra M, Bakema J, Verdaasdonk M et al. Detection of a putative HLA-A 31012 processed (intronless) pseudogene in a laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 27(1), 26-34 (2000).
52. Fujii GH, Morimoto AM, Berson AE, Bolen JB. Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 18(9), 1765-1769 (1999).
53. Tsitsiou E, Williams AE, Moschos SA et al. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J. Allergy Clin. Immunol. 129(1), 95-103 (2012).
54. Chang ST, Sova P, Peng X et al. Next-generation sequencing reveals HIV-1-mediated suppression of T cell activation and RNA processing and regulation of noncoding RNA expression in a CD4+ T cell line. MBio 2(5), pii: e00134-11 (2011).
55. Chiefari E, Iiritano S, Paonessa F et al. Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and Type 2 diabetes. Nat. Commun. 1, 40 (2010).
56. Hirotsune S, Yoshida N, Chen A et al. An expressed pseudogene regulates the messenger-RNA stability of its homologous coding gene. Nature 423(6935), 91-96 (2003).
57. Gray TA, Wilson A, Fortin PJ, Nicholls RD. The putatively functional Mkrn1-p1 pseudogene is neither expressed nor imprinted, nor does it regulate its source gene in trans. Proc. Natl Acad. Sci. USA 103(32), 12039-12044 (2006).
58. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. 15(3), 331-341 (2005).
59. Lee Y, Kim M, Han J et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23(20), 4051-4060 (2004).
60. Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-419 (2003).
61. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363-366 (2001).
62. Liu J, Carmell MA, Rivas FV et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305(5689), 1437-1441 (2004).
63. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl Acad. Sci. USA 100(17), 9779-9784 (2003).
64. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308), 835-840 (2010).
65. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153(3), 654-665 (2013).
66. Yang N, Kazazian HH. L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. Nat. Struct. Mol. Biol. 13(9), 763-771 (2006).
67. Kawaji H, Nakamura M, Takahashi Y et al. Hidden layers of human small RNAs. BMC Genomics 9, 157 (2008).
68. Watanabe T, Totoki Y, Toyoda A et al. Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes. Nature 453(7194), 539-543 (2008).
69. Tam OH, Aravin AA, Stein P et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 453(7194), 534-538 (2008).
70. Chan WL, Yuo CY, Yang WK et al. Transcribed pseudogene yPPM1K generates endogenous siRNA to suppress oncogenic cell growth in hepatocellular carcinoma. Nucleic Acids Res. 41(6), 3734-3747 (2013).
71. Aravin AA, Sachidanandam R, Bourc'his D et al. A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol. Cell 31(6), 785-799 (2008).
72. Aravin AA, Sachidanandam R, Girard A, Fejes-Toth K, Hannon GJ. Developmentally regulated piRNA clusters implicate MILI in transposon control. Science 316(5825), 744-747 (2007).
73. Carmell MA, Girard A, van de Kant HJG et al. MIWI2 is essential for spermatogenesis and repression of transposons in the mouse male germline. Dev. Cell 12(4), 503-514 (2007).
74. Franco-Zorrilla JM, Valli A, Todesco M et al. Target mimicry provides a new mechanism for regulation of microRNA activity. Nat. Genet. 39(8), 1033-1037 (2007).
75. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell 146(3), 353-358 (2011).
76. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465(7301), 1033-1038 (2010).
77. Tay Y, Kats L, Salmena L et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 147(2), 344-357 (2011).
78. Sumazin P, Yang X, Chiu HS et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147(2), 370-381 (2011).
79. Karreth FA, Tay Y, Perna D et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147(2), 382-395 (2011).
80. Trotman LC, Niki M, Dotan ZA et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1(3), E59 (2003).
81. Alimonti A, Carracedo A, Clohessy JG et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42(5), 454-458 (2010).
82. Poliseno L, Haimovic A, Christos PJ et al. Deletion of PTENP1 pseudogene in human melanoma. J. Invest. Dermatol. 131(12), 2497-2500 (2011).
83. Khalil AM, Guttman M, Huarte M et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106(28), 11667-11672 (2009).
84. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010).
85. Mayer C, Schmitz KM, Li J, Grummt I, Santoro R. Intergenic transcripts regulate the epigenetic state of rRNA genes. Mol. Cell 22(3), 351-361 (2006).
86. Yu W, Gius D, Onyango P et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451(7175), 202-206 (2008).
87. Roberts TC, Wood MJA. Therapeutic targeting of non-coding RNAs. Essays Biochem. 54(1), 127-145 (2013).
88. Erba HP, Sayar H, Juckett M et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest. New Drugs 31(4), 1023-1034 (2013).
89. Modarresi F, Faghihi MA, Lopez-Toledano MA et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30(5), 453-459 (2012).
90. Jepsen JS, Wengel J. LNA-antisense rivals siRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 7(2), 188-194 (2004).
91. Ivanova G, Reigadas S, Ittig D et al. Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides 17(1), 54-65 (2007).
92. Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res. 71(1), 3-7 (2011).
93. Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 48(1-2), 259-271 (2013).
94. Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol. Ther. 20(3), 483-512 (2012).
95. Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342(3), 919-927 (2006).